ELN 2022: diagnosis and management of acute myeloid leukaemia in adults
The European LeukemiaNet 2022 recommendations define how acute myeloid leukaemia is classified by its genetics into favourable, intermediate and adverse risk, and how those groups should be treated and monitored.
Overview
International expert panel recommendations updating the 2017 European LeukemiaNet guidance on AML diagnosis, genetic risk classification, response criteria, measurable residual disease and treatment, aligned with the 2022 WHO and International Consensus classifications.
Key changes include FLT3-ITD moving to intermediate risk regardless of allelic ratio, the addition of adverse-risk myelodysplasia-related gene mutations, and new criteria for measurable residual disease assessment.
The risk category on an AML report, and therefore whether a patient is steered towards transplant in first remission, comes from these recommendations.
- Risk categories were derived largely from intensively treated patients and predict less well under venetoclax-based regimens.
Similar pages
not linked directly; found by shared links- Key paperEnasidenib in mutant IDH2 relapsed or refractory acute myeloid leukaemia
Shares Blood, IDH1- and IDH2-mutated acute myeloid leukaemia.
- Key paperAZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts
Shares Blood, Acute myeloid leukaemia in older or unfit patients.
- TrialVIALE-A
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
- TermELN 2022 risk classification
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
- TrialmyeloMATCH
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
- TreatmentCytarabine + anthracycline ('7+3')
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, FLT3-mutated acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
- TrialA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Shares NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients.
- TermHypomethylating agents (azacitidine, decitabine)
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients.